Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value -- Ignore unavailable to you. Want to Upgrade?

To: dalroi who wrote (75)	7/8/2002 10:54:45 AM
From: AurumRabosa	Read Replies (2) \| Respond to of 684

Just scratching the surface on this look at BFLTCV stocks. Some of these I wouldn't buy with your money, e.g. CRA :-} Just to say a biotech company has more cash than its mkt cap doesn't say anything about its future mkt prospects & products. Also, some of these have low cash but deep pocketed partners that are funding their work. I suspect VPHM may fit that bill but I want to read a lot more about them. When I talked to our pediatrician about vaccinating the kids he said we really need a vaccine for RSV which causes the most problems for children. If they have an efficacious RSV vaccine they'd probably have a blockbuster on their hands. If their big pharma partner had seen enough data to convince them of this they would keep them in coin until it hit the market. I just noticed this table on the Signals web site: signalsmag.com which really interests me for the column "Survival Index (Yrs)." Having cash or a good source of it will be essential to survival over the next few years. Do you think this table has any merit?

To: dalroi who wrote (75)	7/9/2002 10:58:14 AM
From: RWReeves	Respond to of 684

Hi Stefaan! Interesting observation that "acla is special case yahoo lists its cash indeed around 70m but when looking into the 10q 35m is restricted cash for payment to calp"... Have you checked to see if CALP records it as a receivable? At one time the award was small potatoes, now it is a fair chunk of change. Not that CALP needs the money badly, but it was hard for ACLA to lose it. CALP is attractive as it has actual sales (ACLA on a more limited basis, would not be surprised to see that one picked up sometime). I noticed ARDM as another combination bio/meddev talked about, and in fairness INHL should also make the list as they are probably near or at cash and have always had some "magic multiple" that kept their valuation (in better times) up there. That seems to have all but vanished recently. General news for inhaled meds has been positive but stock price has not. I have all 4 in the portfolio and managed to lose money on at least 3 of them in the recent past <nvbg>. See you soon..... RWR